As of Apr 17
| -0.14 / -0.86%|
The 5 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 50.00, with a high estimate of 55.00 and a low estimate of 35.00. The median estimate represents a +210.37% increase from the last price of 16.11.
The current consensus among 6 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.